Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SYHX2005 in Patients With Advanced Solid Tumors
Latest Information Update: 14 Nov 2022
At a glance
- Drugs SYHX 2005 (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors CSPC Ouyi Pharmaceutical
- 14 Nov 2022 New trial record